Laboratory Co. of America (LH) Set to Announce Earnings on Thursday

Laboratory Co. of America (NYSE:LHGet Free Report) will issue its quarterly earnings data before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of $3.30 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Laboratory Co. of America Trading Up 2.2 %

Shares of Laboratory Co. of America stock opened at $227.50 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.36 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $19.31 billion, a P/E ratio of 30.41 and a beta of 1.04. Laboratory Co. of America has a 12-month low of $174.20 and a 12-month high of $234.09. The company has a 50-day simple moving average of $223.60 and a 200 day simple moving average of $213.28.

Laboratory Co. of America Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, February 26th. Laboratory Co. of America’s dividend payout ratio is 38.50%.

Wall Street Analysts Forecast Growth

LH has been the topic of several recent analyst reports. TheStreet raised shares of Laboratory Co. of America from a “c+” rating to a “b-” rating in a research note on Thursday, January 18th. JPMorgan Chase & Co. lifted their price target on shares of Laboratory Co. of America from $259.00 to $261.00 and gave the company an “overweight” rating in a research note on Friday, November 17th. Evercore ISI assumed coverage on shares of Laboratory Co. of America in a research note on Friday. They issued an “in-line” rating and a $240.00 price target on the stock. Barclays started coverage on shares of Laboratory Co. of America in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $222.00 price objective on the stock. Finally, Mizuho lowered their target price on shares of Laboratory Co. of America from $257.00 to $230.00 and set a “buy” rating on the stock in a report on Tuesday, October 31st. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Laboratory Co. of America has a consensus rating of “Moderate Buy” and an average price target of $241.86.

Get Our Latest Report on LH

Insider Activity

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total transaction of $57,513.54. Following the completion of the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Der Vaart Sandra D. Van sold 259 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total transaction of $57,513.54. Following the completion of the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Peter J. Wilkinson sold 1,384 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $210.71, for a total value of $291,622.64. Following the completion of the transaction, the chief accounting officer now owns 2,087 shares in the company, valued at $439,751.77. The disclosure for this sale can be found here. 0.65% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Laboratory Co. of America

Large investors have recently made changes to their positions in the business. Lido Advisors LLC purchased a new position in Laboratory Co. of America during the 1st quarter valued at about $232,000. Prelude Capital Management LLC purchased a new position in Laboratory Co. of America during the 2nd quarter valued at about $229,000. Cibc World Market Inc. bought a new stake in shares of Laboratory Co. of America during the 1st quarter valued at about $213,000. Laurel Wealth Advisors Inc. bought a new stake in shares of Laboratory Co. of America during the 4th quarter valued at about $209,000. Finally, Fund Management at Engine No. 1 LLC bought a new stake in shares of Laboratory Co. of America during the 1st quarter valued at about $208,000. 89.37% of the stock is owned by hedge funds and other institutional investors.

Laboratory Co. of America Company Profile

(Get Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.

Featured Stories

Earnings History for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.